NCT05585814

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer

CapeOX Combined With Bevacizumab Plus Pembrolizumab as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer (COBP)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Shanghai Changzheng Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This prospective, single-arm study aims to investigate the efficacy and safety of pembrolizumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS locally advanced rectal cancer patients

Conditions

• Locally Advanced Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Capecitabine	Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 3 cycles
DRUG	Oxaliplatin	Oxaliplatin is given by intravenous infusion at 130mg / m2 on Day 1 every 3 weeks for 3cycles
DRUG	Bevacizumab	Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 3 cycles
DRUG	Pembrolizumab	Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles

Timeline

• Start date: 2023-05-01
• Primary completion: 2024-10-01
• Completion: 2028-05-01
• First posted: 2022-10-19
• Last updated: 2025-03-14

Locations

1 site across 1 country: China